Table 1 Clinicopathological features of metaplastic breast carcinoma, invasive ductal carcinoma and triple-negative invasive ductal carcinoma
| Â | Metaplastic breast cancer (N = 55) | Invasive ductal carcinoma (N = 767) | TN-IDC (N = 131) | ||
|---|---|---|---|---|---|
Features | N (%) | N (%) | P | N (%) | P |
Age | Â | Â | 0.594 | Â | 0.264 |
  ≤50 | 27 (49.09) | 405 (52.80) |  | 76 (58.02) |  |
  >50 | 28 (50.91) | 362 (47.20) |  | 55 (41.98) |  |
Stage | Â | Â | 0.001 | Â | <0.001 |
  I | 4 (7.27) | 107 (13.95) |  | 21 (16.03) |  |
  II | 30 (54.55) | 522 (68.06) |  | 92 (70.23) |  |
  III | 16 (29.09) | 87 (11.34) |  | 8 (6.11) |  |
  Unknown | 5 (9.09) | 51 (6.65) |  | 10 (7.63) |  |
Operation | Â | Â | 0.051 | Â | 0.054 |
  Breast-conserving surgery | 4 (7.27) | 134 (17.47) |  | 25 (19.08) |  |
  Modified radical mastectomy | 51 (92.73) | 633 (82.53) |  | 106 (80.92) |  |
Chemotherapy | Â | Â | 0.302 | Â | 0.295 |
  Yes | 48 (87.28) | 627 (81.74) |  | 106 (80.91) |  |
  No | 7 (12.73) | 140 (18.25) |  | 25 (19.08) |  |
Radiotherapy | Â | Â | <0.001 | Â | <0.001 |
  Yes | 27 (49.09) | 177 (23.08) |  | 29 (22.14) |  |
  No | 28 (50.91) | 590 (76.92) |  | 102 (77.86) |  |
Hormone therapy | Â | Â | <0.001 | Â | Â |
  Yes | 13 (23.64) | 522 (68.06) |  | — |  |
  No | 42 (76.46) | 245 (31.94) |  | — |  |
Pathological tumor stage | Â | Â | <0.001 | Â | <0.001 |
  T1 (≤2 cm) | 5 (9.09) | 317 (41.33) |  | 58 (44.27) |  |
  T2 (2–5 cm) | 22 (40.00) | 332 (43.29) |  | 55 (41.98) |  |
  T3 (>5 cm) | 22 (40.00) | 39 (5.08) |  | 5 (3.82) |  |
  Tx | 6 (10.91) | 79 (10.30) |  | 13 (9.92) |  |
Pathological nodal stage | Â | Â | 0.001 | Â | 0.001 |
  N0 | 35 (63.64) | 314 (41.20) |  | 50 (38.17) |  |
  N1-3 | 15 (27.27) | 385 (49.93) |  | 69 (52.67) |  |
  Nx | 5 (9.09) | 68 (8.87) |  | 12 (9.16) |  |
Histological grade | Â | Â | 0.167 | Â | 0.285 |
  I or II | 29 (52.73) | 461 (60.10) |  | 77 (58.78) |  |
  III | 20 (36.36) | 227 (29.60) |  | 41 (31.30) |  |
  Unknown | 6 (10.91) | 79 (10.30) |  | 13 (9.92) |  |
Ki-67 a | Â | Â | <0.001 | Â | <0.001 |
  ≥14% | 47 (87.27) | 486 (63.36) |  | 80 (61.07) |  |
  <14% | 8 (12.73) | 281 (36.64) |  | 51 (38.93) |  |
P53 b | Â | Â | 0.001 | Â | 0.008 |
  ≥25% | 28 (50.91) | 221 (28.81) |  | 40 (30.53) |  |
  <25% | 27 (49.09) | 546 (71.19) |  | 91 (69.47) |  |
Estrogen receptor | Â | Â | <0.001 | Â | Â |
  + | 8 (14.55) | 419 (54.63) |  | — |  |
  − | 47 (85.45) | 348 (45.37) |  | — |  |
Progesterone receptor | Â | Â | <0.001 | Â | Â |
  + | 10 (18.18) | 492 (64.14) |  | — |  |
  − | 45 (81.82) | 276 (35.98) |  | — |  |
Human epidermal growth factor receptor-2 | Â | Â | 0.005 | Â | Â |
  + | 9 (16.36) | 268 (34.94) |  | — |  |
  − | 46 (83.64) | 499 (65.06) |  | — |  |
TN-MBC | 37 (67.27) | 131 (18.22) | <0.001 | — |  |
Not TN-MBC | 18 (32.73) | 636 (81.78) |  | — |  |